NCT04158076View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

PHASE3CompletedINTERVENTIONAL

Enrollment

131

Participants

Timeline

Start Date

January 23, 2020

Primary Completion Date

January 14, 2021

Study Completion Date

January 14, 2021

Conditions

HypercholesterolemiaHypertension

Interventions

DRUG

Ezetimibe/Rosuvastatin

PO, Once daily(QD), 8weeks

DRUG

Telmisartan

PO, Once daily(QD), 8weeks

DRUG

Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET

PO, Once daily(QD), 8weeks

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Addpharma Inc.

INDUSTRY

NCT04158076 - Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine | Biotech Hunter | Biotech Hunter